|
Status |
Public on Nov 28, 2008 |
Title |
Prediction of survival in diffuse large B cell lymphoma treated with chemotherapy plus Rituximab |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Gene expression profiling of DLBCL patient samples was performed to investigate, whether molecular gene expression signatures retain their prognostic significance in patients treated with chemotherapy plus Rituximab. The lymphnode, germinal center signature and a new angiogenesis signature were combined to a final multivariate model which defined quartile groups among Rituximab-CHOP-treated patients with distinct 3-year overall survival rates. Keywords: clinical history design
|
|
|
Overall design |
The retrospective study included 181 clinical samples from CHOP-treated patients and 233 clinical samples from Rituximab-CHOP-treated patients.
|
|
|
Citation(s) |
19038878, 21546504 |
|
Submission date |
Mar 14, 2008 |
Last update date |
Mar 25, 2019 |
Contact name |
Louis M. Staudt |
E-mail(s) |
lstaudt@mail.nih.gov
|
Phone |
301-402-1892
|
Organization name |
National Cancer Institute
|
Department |
Lymphoid Malignancies Branch
|
Lab |
Louis M Staudt
|
Street address |
9000 Rockville Pike, Bldg 10, Rm 4N114
|
City |
Bethesda |
State/province |
MD |
ZIP/Postal code |
20892 |
Country |
USA |
|
|
Platforms (1) |
GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
Samples (420)
|
|
Relations |
BioProject |
PRJNA107335 |